Prospective Cohort With Hemopathy in Languedoc-Roussillon (HemoDiag)

June 17, 2026 updated by: University Hospital, Montpellier

Prospective Cohort Study of Clinical and Laboratory Data of Patients With Hemopathy in Languedoc-Roussillon

Prospective Cohort Study of clinical and laboratory data of patients with hemopathy.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Prospective Cohort Study of clinical and laboratory data of patients with hemopathy in LR.

Study Type

Observational

Enrollment (Estimated)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Montpellier, France
        • Recruiting
        • Hematology department - UHMontpellier Saint éloi
        • Principal Investigator:
          • GUILLAUME CARTRON
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

patient for suspected haematological disease and justifying further exploration

Description

Inclusion criteria:

  • Age over 18
  • Consultant or hospitalized patient for suspected malignant hemopathy and justifying further exploration or patient with a diagnosis of malignant hemopathy less than 6 months old at the time of signing the consent
  • Having signed an informed consent
  • Affiliated with a social security scheme

Exclusion criteria:

  • Minor or major protected
  • Patients who have received treatment for hematological pathology

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
hematologic malignancy
hematologic malignancy with a sampling of blood
Biological: hematologic malignancy
hematologic malignancy with a sampling of blood
Other Names:
  • hematologic malignancy with a sampling of blood

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Survival with 2 years
Time Frame: 2 years
Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC_QLQ-C30
2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Survival with 5 years
Time Frame: 5 years
Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC_QLQ-C30
5 years
Survival with 10 years
Time Frame: 10 years
Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC_QLQ-C30
10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Montpellier

Investigators

  • Principal Investigator: GUILLAUME CARTRON, University Hospital, Montpellier

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2014

Primary Completion (Estimated)

June 1, 2033

Study Completion (Estimated)

June 1, 2033

Study Registration Dates

First Submitted

April 22, 2014

First Submitted That Met QC Criteria

May 6, 2014

First Posted (Estimated)

May 9, 2014

Study Record Updates

Last Update Posted (Actual)

June 22, 2026

Last Update Submitted That Met QC Criteria

June 17, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 9011

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hematologic Malignancy

Clinical Trials on hematologic malignancy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe